NCT07427160 Prognostic Role of Macular Neovascular Membrane Subtype in Pneumatic Displacement of Macular Hemorrhages
| NCT ID | NCT07427160 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Marco Mazzola |
| Condition | AMD - Age-Related Macular Degeneration |
| Study Type | OBSERVATIONAL |
| Enrollment | 60 participants |
| Start Date | 2025-10-15 |
| Primary Completion | 2026-10-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 60 participants in total. It began in 2025-10-15 with a primary completion date of 2026-10-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study investigates the prognostic value of macular neovascularization (MNV) subtypes in patients treated with pneumatic displacement for submacular hemorrhage. The researchers will compare anatomical and functional outcomes (visual acuity) between PCV, RAP, and other MNV forms within a Caucasian cohort to identify subtype-specific predictors of recovery.
Eligibility Criteria
Inclusion Criteria: * Patients undergoing pneumatic displacement (PD) for submacular hemorrhage (SMH), secondary to macular neovascularization (MNV) * Age 50 years or older at the time of SMH diagnosis * Caucasian ethnicity * SMH involving the central or internal ring of the Early Treatment Diabetic Retinopathy Study (ETDRS) grid (within a 3 mm circumference centered on the fovea) * SMH dimensions equal to or greater than one papillary diameter * Pneumatic displacement treatment performed within 36 hours of SMH diagnosis Exclusion Criteria: * SMH estimated to be present for more than 15 days at the time of diagnosis * SMH secondary to conditions other than MNV * Presence of proliferative diabetic retinopathy in the study eye * Aphakia in the study eye * Inadequate pupillary dilation, media opacities, or other impediments to retinal imaging * Previous pneumatic displacement procedures for SMH in the study eye * Ocular surgery in the 8 weeks preceding the pneumatic displacement intervention * Follow-up duration of less than 6 months following the procedure
Contact & Investigator
marco mazzola, MD
PRINCIPAL INVESTIGATOR
Azienda Sanitaria Universitaria Integrata del Trentino
Frequently Asked Questions
Who can join the NCT07427160 clinical trial?
This trial is open to participants of all sexes, aged 50 Years or older, studying AMD - Age-Related Macular Degeneration. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07427160 currently recruiting?
Yes, NCT07427160 is actively recruiting participants. Contact the research team at marco.mazzola@asuit.tn.it for enrollment information.
Where is the NCT07427160 trial being conducted?
This trial is being conducted at Trento, Italy.
Who is sponsoring the NCT07427160 clinical trial?
NCT07427160 is sponsored by Marco Mazzola. The principal investigator is marco mazzola, MD at Azienda Sanitaria Universitaria Integrata del Trentino. The trial plans to enroll 60 participants.